Abstract
Mantle cell lymphoma is an incurable B-cell malignancy. Treatment of young fit patients is particularly challenging, because careful consideration should be made when building a long-term treatment strategy that would provide longer remissions and increase patients’ quality of life. Most young fit patients achieve long remissions with a combination of immunochemotherapy containing rituximab and high-dose cytarabine, followed by high-dose chemotherapy and autologous stem-cell transplantation. The addition of maintenance therapy with rituximab following autologous stem-cell transplantation prolongs the time to relapse and increases overall survival. Despite an intensive approach, late relapses are common and are usually treated with novel agents.
Original language | English (US) |
---|---|
Pages (from-to) | 861-870 |
Number of pages | 10 |
Journal | Hematology/Oncology Clinics of North America |
Volume | 34 |
Issue number | 5 |
DOIs | |
State | Published - Oct 2020 |
Externally published | Yes |
Keywords
- Autologous stem cell transplantation
- Clinical trials
- Mantle cell lymphoma
- Novel therapeutics
ASJC Scopus subject areas
- Hematology
- Oncology